Shares of UnitedHealth Group Inc (NYSE:UNH) ended Monday session in red amid volatile trading. The shares closed down -1.51 points or -1.08% at $138.49 with 2.72 million shares getting traded. Post opening the session at $139.35, the shares hit an intraday low of $138.02 and an intraday high of $139.72 and the price vacillated in this range throughout the day. The company has a market cap of $133.50 billion and the numbers of outstanding shares have been calculated to be 952.39 million shares.
UnitedHealthcare introduced its 2017 Medicare Advantage and Part D prescription drug plans, building on its market-leading 2016 medical plan growth by featuring continued stability in its Medicare Advantage plans’ premiums and benefits as well as a new low-premium prescription drug plan introduced in collaboration with Walgreens.
The new AARP® MedicareRx Walgreens (PDP) plan, insured through UnitedHealthcare, is designed to appeal to consumers who are looking for the peace of mind that Part D prescription drug coverage offers and appreciate the convenience of shopping at their neighborhood Walgreens or Duane Reade, the plan’s preferred retail pharmacy chains that are included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (WBA).
With its low $22.50 premium as well as $0 co-pays for tier 1 medications and $0 deductible for tier 1 and 2 medications purchased at Walgreens and Duane Reade pharmacies, the plan is an ideal choice for cost-conscious consumers looking to maximize the affordability of their Part D coverage. The $22.50 premium makes it one of the lowest-cost Part D plans available nationwide in 2017.
“The AARP MedicareRx Walgreens plan is a great choice for people seeking affordable coverage and convenient access to their medications at more than 8,000 Walgreens locations nationwide where they can save money on their co-pays, or through home delivery from OptumRx,” said Kent Monical, senior vice president of UnitedHealthcare’s Part D plans.iv
“This collaboration reflects our shared commitment to helping people access the medications they need, while providing the pharmacy services and support they depend on, at affordable prices,” said Brad Fluegel, Walgreens senior vice president, chief healthcare commercial market development officer. “Prescription drug costs continue to be a concern for many Medicare beneficiaries. By working closely with UnitedHealthcare and other business partners, we’re developing innovative solutions to meet the needs of patients.”
Shares of Amgen, Inc. (NASDAQ:AMGN) ended Monday session in green amid volatile trading. The shares closed up +0.53 points or 0.32% at $167.34 with 2.51 million shares getting traded. Post opening the session at $166.05, the shares hit an intraday low of $164.44 and an intraday high of $167.58 and the price vacillated in this range throughout the day. The company has a market cap of $126.26 billion and the numbers of outstanding shares have been calculated to be 748.36 million shares.
Amgen, Inc. (AMGN) announced that the Journal of Clinical Oncology (JCO) published results from the Phase 1/2 ‘205 single-arm trial evaluating BLINCYTO® (blinatumomab) in pediatric patients with Philadelphia chromosome‑negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Based on data from an exploratory pooled analysis of 70 patients who received the recommended dose of BLINCYTO in the Phase 1 or Phase 2 portions of the study, 27 patients (39 percent, 95 percent confidence interval [CI], 27–51 percent) achieved complete remission within the first two cycles.
The most frequent grade ≥3 adverse events (AEs) among the patients who received the recommended dose were anemia (36 percent), thrombocytopenia (21 percent), febrile neutropenia (17 percent), hypokalemia (17 percent) and neutropenia (17 percent). The most common AEs overall were pyrexia (80 percent), anemia (41 percent), nausea (33 percent) and headache (30 percent).
“This study showed that BLINCYTO can induce deep molecular remissions in children with highly refractory, multiply relapsed ALL,” said senior author Lia Gore, M.D., professor of Pediatrics, Medical Oncology and Hematology, University of Colorado Anschutz Medical Campus.
“Pediatric patients with relapsed or refractory Ph- B-cell precursor ALL are in critical need of new treatment options,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “The publication of this data in the Journal of Clinical Oncology provides clinical evidence of the potential of BLINCYTO in this patient population and underscores the significance of the recent regulatory approval for use of BLINCYTO in these patients.”